Glinate 60 mg (Nateglinide)

Product Overview

Effective management of Type 2 diabetes requires a comprehensive approach that combines lifestyle modification with pharmacologic therapy. Glinate 60 mg, manufactured by Glenmark Pharmaceuticals Ltd., belongs to the meglitinide class of oral hypoglycemic agents and is specifically indicated for patients who need additional glycemic control after metformin monotherapy or as an adjunct to other oral antidiabetic drugs. The product is supplied in a convenient strip containing ten tablets, each delivering a precise 60 mg dose of nateglinide. Pack sizes of 60, 90, or 120 tablets allow flexibility for chronic therapy, and the medication is shipped within six to fifteen days to most major markets. All formulations are produced under Glenmark’s GMP‑certified facilities, ensuring consistency, potency, and safety for patients seeking reliable diabetes care.

What is Glinate 60 mg (Nateglinide)?

What is Glinate 60 mg (Nateglinide)? Glinate is the brand name for the active ingredient nateglinide, a short‑acting oral medication that belongs to the meglitinide family, a structural class distinct from sulfonylureas and DPP‑4 inhibitors. The drug is chemically described as (R)-2‑[[(1‑oxo‑2‑pyrrolidinyl)methyl]amino]‑2‑oxo‑N‑(4‑methoxyphenyl)‑acetamide, and it functions as a potent inhibitor of the pancreatic beta‑cell ATP‑sensitive potassium channel complex. By blocking this channel, nateglinide reduces the influx of calcium into beta cells, thereby decreasing the rate of insulin release in response to rising blood glucose after meals. This mechanism provides a rapid, post‑prandial glucose‑lowering effect without causing excessive insulin secretion during fasting states, which differentiates it from longer‑acting sulfonylureas.

Uses and Benefits

Uses and Benefits The primary clinical use of Glinate 60 mg is to improve glycemic control in adults with Type 2 diabetes mellitus who have not achieved target HbA1c levels with diet and exercise alone. When administered before the main meals, the medication blunts the post‑prandial spike in glucose, leading to lower average blood sugar concentrations and reduced risk of hyperglycemic complications such as diabetic ketoacidosis. Clinical trials have demonstrated that patients receiving nateglinide experience a modest but statistically significant reduction in fasting plasma glucose and a mean decrease in HbA1c of approximately 0.5 % when combined with metformin. Additional benefits include improved beta‑cell preservation, as the drug’s short duration of action lessens chronic insulin exposure, and a favorable weight‑neutral profile that makes it suitable for patients who are overweight or obese.

How It Works

How It Works The pharmacologic action of nateglinide is rooted in its high affinity for the Kir6.2 subunit of the ATP‑sensitive potassium channel on pancreatic beta cells. Binding of the drug to this channel prevents the efflux of potassium ions, which in turn inhibits the opening of voltage‑gated calcium channels. The resulting reduction in intracellular calcium concentration limits the exocytosis of insulin granules, producing an insulin release that is tightly coupled to the rise in blood glucose after food intake. Because the effect wanes quickly — typically within two to three hours — the medication does not stimulate insulin secretion during fasting periods, thereby minimizing the risk of hypoglycemia. This rapid onset and short half‑life also allow clinicians to fine‑tune dosing based on individual meal patterns and renal function, enhancing therapeutic precision.

Dosage Guidelines

Dosage Guidelines Glinate 60 mg is typically prescribed as one tablet taken orally within 30 minutes before the principal meals of the day, usually the breakfast and dinner. The initial dose may be titrated upward by 30 mg increments at intervals of one to two weeks, guided by fasting plasma glucose measurements and individual tolerability, up to a maximum of 120 mg per day divided into three doses. For patients with moderate to severe renal impairment (estimated glomerular filtration rate less than 60 mL/min per 1.73 m²) the recommended starting dose is 30 mg before each main meal to avoid accumulation. Adjustments are also required in patients with hepatic dysfunction, where the dose should not exceed 60 mg per day. Comprehensive dosing information is available from the U.S. Food and Drug Administration’s prescribing information (FDA prescribing information). Patients should be instructed to swallow the tablet whole with water and to avoid skipping doses that would lead to missed coverage of post‑prandial glucose spikes.

Side Effects

Side Effects Like all pharmacologic agents, Glinate 60 mg can elicit adverse reactions, although most are mild and transient. The most frequently reported side effects include headache, dizziness, and mild hypoglycemia, particularly when the drug is combined with other insulin secretagogues or insulin therapy. Gastrointestinal disturbances such as nausea, abdominal discomfort, and occasional diarrhea have also been documented. Rare but clinically important events comprise hepatic enzyme elevations, which necessitate periodic monitoring of alanine aminotransferase and aspartate aminotransferase, and hypersensitivity reactions ranging from skin rash to, in exceptional cases, anaphylaxis. Patients experiencing persistent gastrointestinal symptoms, unexplained fatigue, or signs of liver dysfunction should contact their healthcare provider promptly. For a complete list of reported events, refer to the Drugs.com database.

Warnings and Precautions

Warnings and Precautions Prior to initiating therapy with Glinate 60 mg, clinicians should assess patient history for type 1 diabetes, diabetic ketoacidosis, or a history of pancreatitis, as the drug is not indicated for these conditions. Caution is advised in individuals with severe renal or hepatic impairment, as altered metabolism may increase the risk of hypoglycemia or drug accumulation. Concomitant use with strong CYP3A4 inhibitors such as ketoconazole or clarithromycin may enhance plasma concentrations of nateglinide, requiring dose reduction. Pregnant and lactating women should avoid the medication unless the benefits clearly outweigh the potential risks, and a thorough discussion with a qualified obstetric provider is recommended. Additionally, patients should be aware that alcohol consumption can potentiate the hypoglycemic effect, and they should monitor blood glucose more frequently when initiating therapy. Full prescribing details, including contraindications and drug interaction tables, are published by the National Institutes of Health’s National Library of Medicine (MedlinePlus drug information).

Frequently Asked Questions

Q: What is the recommended starting dose of Glinate 60 mg? A: The usual starting dose is one tablet (60 mg) taken before the first main meal of the day, with possible dose adjustments based on blood glucose response.

Q: Can Glinate 60 mg be used in patients with kidney disease? A: Yes, but dose reduction is required for moderate to severe renal impairment; a lower starting dose of 30 mg before each meal is advised.

Q: How does Glinate differ from other diabetes medications? A: Glinate belongs to the meglitinide class and works by inhibiting insulin release only after meals, providing a short‑acting effect that reduces the risk of hypoglycemia compared with longer‑acting sulfonylureas.

Q: Are there any dietary restrictions while taking Glinate? A: No specific dietary restrictions exist, but patients should take the medication before meals to achieve optimal post‑prandial glucose control.

Q: Where can I find more detailed prescribing information? A: Detailed prescribing information is available from the FDA’s drug label (FDA prescribing info) and from MedlinePlus (MedlinePlus).

Related Products

• Glizid 80 mg (Gliclazide)
• Candid B Cream (Clotrimazole/Beclometasone)
• Candid Cream (Clotrimazole)
• Semanize 4 mg (Semaglutide)
• Semaglutide 4 mg (Generic)
• Diabetrol Tablets 5 mg/500 mg (Glibenclamide Metformin)
• Glucobay 50 mg (Acarbose)
• Glycomet 850 mg (Metformin)
• Glypride 4 mg (Glimepiride)
• Mignar 25 mg (Miglitol)
• PPG 0.3 mg (Voglibose)
• Prandial 0.3 MD (Voglibose)